Welcome

Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and
others concerned about HIV/AIDS. Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the
conversation yourself by registering on the left side of this page.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive
and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a
username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own
physician.

All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators
of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please
provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are
true and correct to their knowledge.

Michael CarterPublished: 06 February 2013Adding maraviroc and raltegravir to standard HIV treatment regimens achieves rapid suppression of viral load in semen, Canadian investigators report in the online edition of the Journal of Infectious Diseases. Intermittent, low level shedding of HIV in semen was also less likely to occur in people taking intensified therapy than in people treated with a standard three-drug regimen.

HIV treatment that suppresses viral load to undetectable levels has been shown to reduce the risk of transmission by up to 96%. There is a growing consensus that antiretroviral therapy has an important role in prevention. However, virus has occasionally been detected in the genital fluids of people who have an undetectable blood viral load, and there have been isolated case reports of transmissions in such cases.

Investigators in Toronto had previously found that the antiretroviral drugs maraviroc (Celsentri) and raltegravir (Isentress) had good penetration into semen. They therefore wanted to see if intensifying standard antiretroviral treatment with the addition of these drugs reduced the frequency of intermittent shedding of virus in semen.

Their study population comprised 13 gay men who started HIV treatment with the intensified regimen and 25 controls who received standard triple-drug therapy. None had a sexually transmitted infection, a known factor associated with shedding of virus in semen.

Paired blood and semen samples were obtained over two years.

People treated with the intensified regimen had a higher nadir (lowest ever) CD4 cell count and lower baseline viral load in blood than the men who were treated with the standard combination (340 vs 213 cells/mm3; p = 0.001; 7000 vs 50,000 copies/ml, p = 0.05). However, baseline viral load in semen was similar (5136 vs 2979 copies/ml).

Viral load in semen fell more rapidly among the men taking intensified therapy, who were significantly more likely than those treated with a standard regimen to have undetectable viral load in semen after two weeks of therapy (12/13 vs 20/26, p = 0.036).

“Individuals initiating an intensified ART regimen were more likely to achieve virologic suppression in semen by two weeks,” comment the investigators.

Isolated shedding of virus in semen was detected in 48% of participants taking standard treatment compared to 15% of men taking the intensified regimen, a significant difference (p = 0.048).

Restricting analysis to men with an undetectable viral load in their blood showed that intensified therapy was associated with a reduced frequency of shedding of virus in semen (7 vs 15%).

High level shedding in semen (viral load above 5000 copies/ml) was observed in 16% of men treated with a three-drug regimen and one participant (8%) whose therapy also included maraviroc and raltegravir.

One man with an undetectable viral load in his blood continued to have detectable viral load in his semen for 14 months after commencing intensified treatment.

This prompted the investigators to see if virus continued to be shed in the semen of men taking long-term HIV therapy.

They examined paired blood and semen samples obtained from 26 additional men who had been taking long-term standard antiretroviral treatment, in some cases for over five years. All had an undetectable viral load in blood and no sexually transmitted infections.

Approximately half the men who had been taking treatment for under six months had virus intermittently detectable in semen; this fell to 20% of men who had been taking therapy for between one and three years; but no man treated for over three years had virus detectable in semen.

“It is encouraging that IHS was not observed after prolonged ART,” write the authors.

The authors believe their results support research showing that effective HIV therapy has a significant impact on the risk of transmission.

Nevertheless, they conclude “it remains clear that IHS, potentially at very high levels, can occur despite effective antiretroviral therapy, even with the addition of agent with enhanced semen penetration…whether the phenomenon of IHS relates to actual transmission is not known.”

I really doubt that it will work, but nobody knows. The theory is, that after 10 years of intensive ART (2 NRTI + 1 PI/r + Maraviroc + Raltegravir, HDAC-Inhibitors) the latent reservoirs will be depleted. I can't imagine that, but we will see.